TherapyX Inc.

  • Home
  • TherapyX Inc.

TherapyX Inc. THERAPYX INC.

IS A PRIVATELY HELD EARLY STAGE BIOTECHNOLOGY COMPANY ENGAGED IN THE DISCOVERY AND DEVELOPMENT OF NANOPARTICULATE IMMUNE THERAPEUTICS TO TREAT CANCER, INFECTIOUS DISEASE AND AUTOIMMUNE DISORDERS.

14/06/2018

Buffalo, New York – June 8th, 2018 Therapyx, Inc. is pleased to announce a new SBIR Phase I award to explore development of micro-encapsulated Epigallocatechin gallate (EGCG), the most abundant catechin in green tea and the subject of extensive basic research for its potential to affect human heal...

24/05/2018

We've received 10 likes for our newly created page! Thank you for the thumbs up!

THERAPYX INC. IS A PRIVATELY HELD EARLY STAGE BIOTECHNOLOGY COMPANY ENGAGED IN THE DISCOVERY AND DEVELOPMENT OF NANOPARTICULATE IMMUNE THERAPEUTICS TO TREAT CANCER, INFECTIOUS DISEASE AND AUTOIMMUNE DISORDERS.

16/05/2018

Buffalo, New York- June 20, 2017. TherapyX is pleased to announce a SBIR Phase IIb award to continue development of TreXTAMTM it’s first-in-class immune therapy for the treatment of inflammatory bowel disease (IBD) and potentially systemic lupus erythematosus (SLE). TreXTAMTM is a combination of p...

Please join us in celebrating our new website! Click below to find out more about who we are and what we do.
12/05/2018

Please join us in celebrating our new website! Click below to find out more about who we are and what we do.

Using revolutionary technology, TherapyX encapsulates large biological molecules in an orally ingestible form. These molecules remain fully intact and are transported to affected tissue to treat cancer, infectious disease, and autoimmune disorders.

12/05/2018

Buffalo, NY-March 14, 2017 TherapyX is pleased to announce a new SBIR Phase II award to continue development of NGoXIM, a completely novel prophylactic vaccine against ge***al tract infections including Gonorrhea. The award entitled “Experimental Gonococcal Vaccine” will fund preclinical studies...

12/05/2018

Buffalo, NY-November 3, 2016 TherapyX is pleased to announce a new SBIR Phase I award to test its novel product, IL10NanoCap, a completely new nano encapsulated oral formulation of the key regulatory cytokine interleukin 10 (IL-10), in rodent models of inflammatory bowel disease. The NIH SBIR award,...

Address


Website

Alerts

Be the first to know and let us send you an email when TherapyX Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

  • Want your business to be the top-listed Engineering Company?

Share